LEADER 03978nam 22005895 450 001 9910409693003321 005 20250610110407.0 010 $a3-030-33679-4 024 7 $a10.1007/978-3-030-33679-0 035 $a(CKB)4100000011254820 035 $a(MiAaPQ)EBC6202722 035 $a(DE-He213)978-3-030-33679-0 035 $a(PPN)24839231X 035 $a(MiAaPQ)EBC29081105 035 $a(EXLCZ)994100000011254820 100 $a20200519d2020 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aSubstance Use Disorders $eFrom Etiology to Treatment /$fedited by Michael A. Nader, Yasmin L. Hurd 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (x, 502 pages) 225 1 $aHandbook of Experimental Pharmacology,$x1865-0325 ;$v258 311 08$a3-030-33678-6 320 $aIncludes bibliographical references. 327 $a1. Methods for Population Research on Substance Use and Consequences -- 2. Translational Molecular Approaches in Substance Abuse Research -- 3. Small Molecule Neuropeptide-S and Melanocortin Receptor Ligands As Potential Treatments for Substance Use Disorders -- 4. Emerging Insights into Mu Opioid Pharmacology -- 5. Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors -- 6. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research -- 7. Clinical Trials for Opioid Use Disorder -- 8. Modelling Differential Vulnerability to Substance Use Disorder in Rodents: Neurobiological Mechanisms -- 9. Activity-Dependent Epigenetic Remodeling in Cocaine Use Disorder -- 10. Molecular Mechanisms of Amphetamines -- 11. Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes -- 12. Molecular Mechanism and Cannabinoid Pharmacology -- 13. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents -- 14. Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence -- 15. Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade -- 16. Adolescent Vulnerability to Alcohol Use Disorder: Neurophysiological Mechanisms from Preclinical Studies -- 17. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies -- 18. Newly Emerging Drugs of Abuse. 330 $aThe purpose of this book is to provide a broad scope of substance use disorder research and how these findings can impact treatment outcomes. The research and outcomes described in this book represent important principles related to identifying and understanding factors related to substance use disorders. The first section is dedicated to methodology including population-based surveys, basic neuroanatomy, chemistry, molecular biology, behavioral models and brain imaging. The second section utilizes this methodology in research related to opioids, cocaine, marijuana, alcohol and nicotine. The book is aimed at both professionals (academics, clinicians, practitioners) and students or trainees. 410 0$aHandbook of Experimental Pharmacology,$x1865-0325 ;$v258 606 $aPharmacology 606 $aPharmacology 606 $aMalalties mentals$2thub 606 $aFarmacologia$2thub 606 $aDrogues$2thub 608 $aLlibres electrònics$2thub 615 0$aPharmacology. 615 14$aPharmacology. 615 7$aMalalties mentals. 615 7$aFarmacologia 615 7$aDrogues 676 $a616.86 702 $aNader$b Michael A$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHurd$b Yasmin L$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910409693003321 996 $aSubstance use disorders$91765305 997 $aUNINA